Bimatoprost versus Mometasone Furoate in the Treatment of Scalp Alopecia Areata: A Pilot Study

    January 2015 in “Dermatology
    Hesham Zaher, Heba I. Gawdat, Rehab A. Hegazy, Marwa A. Hassan
    Image of study
    TLDR Bimatoprost was found to be safer and more effective than mometasone furoate for treating scalp hair loss.
    In a pilot study involving 30 adult patients with patchy scalp alopecia areata (AA), bimatoprost 0.03% solution demonstrated a significantly higher mean hair regrowth rate (48.95%) compared to mometasone furoate 0.1% cream (22.4%), as well as a quicker initial response time (1.48 weeks vs. 3.57 weeks). Bimatoprost-treated patches also had a lower incidence of resistance (16.7% vs. 43.3%) and relapse (4% vs. 11.8%) than corticosteroid-treated patches, with no side effects reported, while corticosteroid-treated patches had side effects in 58.8% of cases. The study suggests that bimatoprost is a safe and more effective alternative to corticosteroids for the treatment of scalp AA, although it is more expensive. Further large-scale studies are recommended to confirm these findings.
    View this study on karger.com →

    Cited in this study

    Related